Predictive Parameters of a Worse Prognosis in Patients with G2 Neuroendocrine Tumors Treated with Peptide Radio Receptorial Therapy

被引：0
|
作者：
Jandric, J. [1 ]
Laffi, A. [1 ]
Muraglia, L. [1 ]
Zanca, R. [1 ,2 ]
Rodari, M. [1 ]
Evangelista, L. [1 ,2 ]
机构：
[1] IRCCS Humanitas Res Hosp, Rozzano, Italy
[2] Humanitas Univ, Pieve Emanuele Milano, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0598
引用
收藏
页码：S669 / S670
页数：2
相关论文
共 50 条
  • [31] Is proliferative index (Ki-67) useful to stratify patients (pts) with G2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)? Clinicopathologic correlation.
    Angel, Martin
    Connor, Juan O.
    Pesce, Veronica
    Ariel Mendez, Guillermo
    Bestani, Claudia
    Marmissolle, Fabiana
    Giacomi, Nora
    Belli, Susana
    Domenichini, Enzo
    Chacon, Matias
    Zamora, Victor
    Maria Cabanne, Ana
    Parma, Patricia
    Luis Roca, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [32] Prognostic value of the volumetric parameters measured by SSTR PET/CT in patients with neuroendocrine tumors treated with long-acting somatostatin analogues as a first line therapy
    Opalinska, M.
    Morawiec-Slawek, K.
    Lenda-Tracz, W.
    Sowa-Staszczak, A.
    Hubalewska-Dydejczyk, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S663 - S663
  • [33] Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy Experience From a Tertiary Referral Center
    Khetan, Prerna
    Oyewole, Femi
    Wolin, Edward
    Kim, Michelle Kang
    Divino, Celia M.
    PANCREAS, 2020, 49 (04) : 509 - 513
  • [34] Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)
    Capdevila, J.
    Fazio, N.
    Lopez, C.
    Teule, A.
    Valle, J. W.
    Tafuto, S.
    Custodio, A.
    Reed, N.
    Raderer, M.
    Grande, E.
    Garcia-Carbonero, R.
    Jimenez Fonseca, P.
    Alonso, V.
    Antonuzzo, L.
    Spallanzani, A.
    Berruti, A.
    Sevilla Garcia, I.
    La Casta, A.
    Hernando, J.
    Ibrahim, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 467 - 467
  • [35] Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT
    Durmo, Rexhep
    Filice, Angelina
    Fioroni, Federica
    Cervati, Veronica
    Finocchiaro, Domenico
    Coruzzi, Chiara
    Besutti, Giulia
    Fanello, Silvia
    Frasoldati, Andrea
    Versari, Annibale
    CANCERS, 2022, 14 (03)
  • [36] Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
    Ortega, Claudia
    Wong, Rebecca K. S.
    Schaefferkoetter, Josh
    Veit-Haibach, Patrick
    Myrehaug, Sten
    Juergens, Rosalyn
    Laidley, David
    Anconina, Reut
    Liu, Amy
    Metser, Ur
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (10) : 1406 - 1414
  • [37] Efficacy and Safety Analyses of the TALENT Trial (GETNE 1509): A Phase II Study of Lenvatinib in Patients (pts) with Advanced G1/G2 Pancreatic (panNETs) and Gastrointestinal (giNETs) Neuroendocrine Tumors
    Capdevila, J.
    Bongiovanni, A.
    Hernando, J.
    Spada, F.
    Lopez, C.
    Teule, A.
    Merino, X.
    Lamarca, A.
    Tafuto, S.
    Custodio, A.
    Fazio, N.
    Ibrahim, T.
    NEUROENDOCRINOLOGY, 2019, 108 : 168 - 168
  • [38] Quantitative somatostatin receptor image assessment for survival prediction: a full-body, longitudinal, individual lesion analysis of neuroendocrine tumors in patients treated with peptide receptor radiation therapy
    Santoro-Fernandes, V.
    Schott, B.
    Deatsch, A.
    Keigley, Q.
    Francken, T.
    Meeker, R.
    Lyer, R.
    Christos, F.
    Perlman, S.
    Jeraj, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S314 - S315
  • [39] A review of the Scottish national Peptide Receptor Radionuclide Therapy (PRRT) service with focus on patients with small bowel neuroendocrine tumors (SBNET) treated between April 2019 and March 2021
    Wotherspoon, I
    Charlick, A.
    McIntosh, D.
    Reed, N.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 257 - 257
  • [40] Is proliferative index (Ki 67) useful to stratify patients (pts) with G2 gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)? Clinicopathologic correlation.
    Connor, Juan O.
    Angel, Martin
    Pesce, Veronica
    Ariel Mendez, Guillermo
    Bestani, Claudia
    Marmissolle, Fabiana
    Giacomi, Nora
    Belli, Susana
    Domenichini, Enzo
    Chacon, Matias
    Zamora, Victor
    Maria Cabanne, Ana
    Parma, Patricia
    Luis Roca, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345